Marc Goodman
Stock Analyst at Leerink Partners
(3.61)
# 804
Out of 5,157 analysts
95
Total ratings
57.14%
Success rate
21.23%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGP SpyGlass Pharma | Initiates: Outperform | $42 | $26.82 | +56.60% | 1 | Mar 3, 2026 | |
| MANE Veradermics | Initiates: Outperform | $75 | $50.65 | +48.08% | 1 | Mar 2, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $150 → $205 | $166.34 | +23.24% | 8 | Jan 28, 2026 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | $8 | $3.26 | +145.40% | 1 | Jan 12, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $18.97 | +58.14% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $2.13 | +134.74% | 1 | Nov 17, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $24.02 | +41.55% | 1 | Oct 6, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $10.27 | +386.85% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $14.98 | -33.24% | 5 | May 7, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $6.62 | -84.89% | 3 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $32 | $11.94 | +168.01% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $174.00 | -85.63% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $21.43 | +133.32% | 1 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $5.28 | +278.79% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $129.86 | -11.44% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $188.41 | +64.53% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $60.61 | -24.10% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $22.54 | -6.83% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $185.93 | +12.95% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.04 | +228.95% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $27.74 | -2.67% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.01 | +199.40% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $647.23 | -58.28% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $227.01 | -57.71% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $60.13 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $117.09 | -42.78% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $10.10 | +870.30% | 7 | Oct 5, 2017 |
SpyGlass Pharma
Mar 3, 2026
Initiates: Outperform
Price Target: $42
Current: $26.82
Upside: +56.60%
Veradermics
Mar 2, 2026
Initiates: Outperform
Price Target: $75
Current: $50.65
Upside: +48.08%
Axsome Therapeutics
Jan 28, 2026
Maintains: Outperform
Price Target: $150 → $205
Current: $166.34
Upside: +23.24%
Neumora Therapeutics
Jan 12, 2026
Initiates: Outperform
Price Target: $8
Current: $3.26
Upside: +145.40%
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $18.97
Upside: +58.14%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $2.13
Upside: +134.74%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $24.02
Upside: +41.55%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $10.27
Upside: +386.85%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $14.98
Upside: -33.24%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $6.62
Upside: -84.89%
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $11.94
Upside: +168.01%
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $174.00
Upside: -85.63%
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $21.43
Upside: +133.32%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $5.28
Upside: +278.79%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $129.86
Upside: -11.44%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $188.41
Upside: +64.53%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $60.61
Upside: -24.10%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $22.54
Upside: -6.83%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $185.93
Upside: +12.95%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.04
Upside: +228.95%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $27.74
Upside: -2.67%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.01
Upside: +199.40%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $647.23
Upside: -58.28%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $227.01
Upside: -57.71%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $60.13
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $117.09
Upside: -42.78%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $10.10
Upside: +870.30%